6533b82afe1ef96bd128b8b3

RESEARCH PRODUCT

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer

Saori MishimaJ.b. AhnP-c LinA. OhtsuMyung Ah LeeH.h. HasbullahC.e. CheeSolange PetersDirk ArnoldC. ChuaI. FaudTakeharu YamanakaHiroya TaniguchiArundhati SharmaAndrés CervantesB.k. SmrutiFlorian LordickEiji OkiY.x. LiErika MartinelliChikashi IshiokaY. SunG. ArgilésEishi BabaGiuseppe CuriglianoJosep TaberneroHiroko BandoGeorgios PentheroudakisTakayuki YoshinoK.-h. Yeh

subject

medicine.medical_specialtyAsiaColorectal cancerDrug availabilityEthnic grouplocalised colon cancerMedical OncologyScientific evidenceFollow-Up StudieRepublic of KoreaAsian countryMedicineReimbursementColonic NeoplasmPan-Asiantreatmentbusiness.industryHematologyESMOmedicine.diseaseClinical PracticediagnosiOncologyDiagnosis treatmentFamily medicinebusinessguidelineHuman

description

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of localised colon cancer was published in 2020. It was decided by both the ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special virtual guidelines meeting in March 2021 to adapt the ESMO 2020 guidelines to take into account the ethnic differences associated with the treatment of localised colon cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with localised colon cancer representing the oncological societies of Japan (JSMO), China (CSCO), India (ISMPO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug availability and reimbursement situations in the different Asian countries.

yearjournalcountryeditionlanguage
2021-12-01
10.1016/j.annonc.2021.08.1752http://hdl.handle.net/11591/463715